Anti-Human PSMA1 (Clone CPTC-PSMA1-1) – Purified No Carrier Protein

Synthetic Peptide ETLPAEQDLTTK

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0133E-5G8-H1/K1 activity is directed against human PSMA1 peptide sequence ETLPAEQDLTTK.

CPTC-PSMA1-1

PSMA1 is a highly ordered, ring-shaped, 20S multicatalytic proteinase complex that is a member of the 26S proteasome¹, a proteolytic complex essential to normal protein turnover² and immune response³. The 26S proteosome is composed of a 20S catalytic core particle capped at either or both ends by 19S regulatory particles and is responsible for the degradation of ubiquitinated proteins. PSMA1 is a structural subunit essential to the assembly of the 20S subcomplex. The 20S catalytic core is composed of 28 subunits arranged into four stacked rings that participate in substrate recognition, entry into the proteosome, and proteolysis².

In normal metabolism, the 26S proteosome plays a role in nearly all cellular processes by eliminating proteins that are misfolded, oxidized, or no longer needed³. Additionally, specialized proteosomes called immunoproteosomes are expressed at high levels in antigen-presenting cells and generate antigenic peptides from intracellular antigens that interact with MHC class I molecules. Immunoproteosomes are essential to host recognition of tumor cells³. Dysregulation of PSMA1 plays a role in the progression of cancer and is therefore a potential target for immunotherapy¹. Additionally, PSMA1 is essential to meiosis during spermatogenesis and lack of function leads to infertility².

EB0133E-5G8-H1/K1 was generated for use in immuno-MRM assays in rabbit using a synthetic peptide derived from residues 197-208 of human PSMA1, ETLPAEQDLTTK⁴. EB0133E-5G8- H1/K1 can be used in immunohistochemistry, immunofluorescence, and Western blot analysis to detect PSMA1⁵. EB0133E-5G8-H1/K1 does not detect PSMA1 in reverse phase protein arrays.

PSMA1 is ubiquitously expressed throughout eukaryotic cells as a member of the 26S proteosome complex. PSMA1 is significantly upregulated in colon cancer and gastric cancer tissues. PSMA1 localizes to the cytoplasm and nucleus.

PA28α/β proteasome activator, AKIRIN2

1 Yang Q, Lu Y, Shangguan J, et al. Cell Death Dis. 13(11):989. 2022.
2 Han TT, Wang LY, Zhou QX, et al. Zool Res. 46(1):27-40. 2025.
3 Rana PS, Ignatz-Hoover JJ, Guo C, et al. Mol Cancer Ther. 23(12):1743-1760. 2024.
4 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
5 https://antibodies.cancer.gov/detail/CPTC-PSMA1-1